Notice of Intent to Publish a Funding Opportunity Announcement for Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
ID: 356540Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356540
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Viral INfections in the Young Lung (VINYL) Clinical Consortium, aimed at supporting research on severe viral lower respiratory tract infections (LRTI) in children aged 0-2 years. This initiative will involve the establishment of a consortium to phenotype affected children and follow them until preschool age to assess pulmonary sequelae, utilizing a phased award structure to fund various centers, including a Data and Analytics Coordinating Center and multiple Clinical Centers. The total funding available is projected to be up to $31.6 million, with the NOFO expected to be published in February 2025 and applications due by June 2025, leading to funding decisions anticipated in February 2026. Interested applicants should prepare their proposals in advance of these deadlines.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming opportunity for a cooperative agreement titled "Viral INfections in the Young Lung- The VINYL Clinical Consortium (UG3/UH3 Clinical Trial Optional)." This initiative aims to support a consortium focused on phenotyping children aged 0-2 years who experience severe viral lower respiratory tract infections (LRTI), with follow-up assessments until preschool age to evaluate pulmonary sequelae. The program is significant for advancing research in pediatric respiratory health and will utilize the UG3/UH3 activity code for funding, with applications not currently being solicited to allow potential applicants time to prepare. Interested parties can reach out to the Division of Lung Diseases at NHLBI via email at nhlbidldgrants@nhlbi.nih.gov for further information, with an estimated synopsis posting date of August 22, 2025, and a projected award date of May 1, 2026.
    Viral INfections in the Young Lung- The VINYL Clinical Consortium- Data Analytics and Coordinating Center (DACC) (U24 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Viral INfections in the Young Lung (VINYL) Clinical Consortium, specifically for the Data Analytics and Coordinating Center (DACC) under a cooperative agreement. This initiative aims to support research on severe viral lower respiratory tract infections (LRTI) in children aged 0-2 years, with a focus on understanding pulmonary sequelae through a consortium approach that includes clinical centers and a biorepository. The opportunity is part of the NIH's mission to advance health research and is categorized under discretionary funding with no cost-sharing requirements. Interested applicants, particularly small businesses with relevant expertise, are encouraged to prepare for future applications, as the estimated synopsis will be posted on August 22, 2025, with a closing date of October 22, 2025, and an anticipated award date of May 1, 2026. For further inquiries, potential applicants can contact the Division of Lung Diseases at NHLBI via email at nhlbidldgrants@nhlbi.nih.gov.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for HIV Pediatric, Adolescent and Maternal Clinical Trials
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on high-priority HIV studies targeting infants, children, adolescents, young adults, and maternal populations. This initiative aims to establish an HIV clinical trials network dedicated to these demographics, fostering innovative and collaborative clinical trials to address significant research areas in HIV and related health issues. The estimated total program funding is $30 million, with two awards anticipated, and potential applicants are encouraged to begin forming collaborations and developing proposals ahead of the expected synopsis posting on November 21, 2025. For further inquiries, interested parties may contact Dr. Sonia Lee at Sonia.lee@nih.gov or by phone at 301-594-4783.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Funding Opportunity Announcement (FOA) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to enhance the diagnosis, management, and treatment of rare diseases through collaborative, multi-site, patient-centric research, with a focus on addressing unmet clinical trial readiness needs. The estimated total program funding for this opportunity is $1,000,000, with the FOA expected to be published in 2024 and applications due later that year. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Notice of Intent to Publish the re-issuance of the Notice of Funding Opportunity (NOFO) Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to re-issue the Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) under the Rare Diseases Clinical Research Network (RDCRN), aimed at enhancing research in the diagnosis, management, and treatment of rare diseases. Each RDCRC is required to focus on at least three rare diseases and propose two to four clinical research projects, including one longitudinal study, emphasizing a collaborative, multi-site approach to address significant clinical trial readiness gaps. This initiative reflects the government's commitment to advancing public health through innovative methodologies and stakeholder engagement in the rare disease domain, with applications expected to be due in June and fall of 2025. Interested applicants can reach out to Dr. Tiina K. Urv at 301-827-2746 or via email at urvtiin@mail.nih.gov for further information.
    Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for pilot projects aimed at enhancing the Human Virome Program through a grant titled "Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)." This initiative seeks to support small businesses in developing innovative projects that advance the understanding of the healthy human virome, including its characterization, tools, and interactions with the host, while ensuring that proposed projects do not overlap with existing efforts. With an estimated total program funding of $2,000,000 and the expectation of awarding six grants, interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on September 15, 2025. For further inquiries, potential applicants can contact Amanda Melillo, PhD, at amanda.melillo@nih.gov or by phone at 301-529-7217.
    Notice of Intent to Publish a Funding Opportunity Announcement for NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the NHLBI SBIR Phase IIB Small Market Awards aimed at accelerating the commercialization of technologies for heart, lung, blood, and sleep disorders. This funding opportunity is designed to support small businesses in advancing promising biomedical projects that have previously received SBIR or STTR Phase II funding, specifically targeting products that address rare diseases or pediatric populations. With an estimated total program funding of $21 million and an award ceiling of $3.5 million, the anticipated application due date is February 25, 2025, with awards expected to be made by December 1, 2025. Interested applicants are encouraged to prepare their proposals in advance to meet the requirements integral to this initiative.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for High-Priority Research in Tobacco Regulatory Science, inviting R01 research applications that focus on biomedical and behavioral research to inform tobacco product regulation. This initiative aims to generate scientific data that will enhance public health protections related to tobacco use, with a particular emphasis on fostering diverse perspectives through a simplified peer review framework. The total estimated funding for this program is $4 million, with an award ceiling of $500,000 for each of the anticipated five awards, and the NOFO is expected to be published in Winter 2024, with applications due in Summer 2025. Interested applicants should prepare to submit new applications, as only new proposals will be considered, and further details will be available upon the official release of the NOFO.